This article was originally published in The Tan Sheet
Executive SummaryGerman firm is considering divestiture of its Pharmaton Business as part of an ongoing review of its over-the-counter portfolio while weighing "the merits of alternative options," the company announced Sept. 9. The country's top drug maker by sales issued the statement in response to "rumors circulating in the market regarding a potential sale of parts of the Consumer Health Care Business." The segment up for review affects multivitamin and ginseng products sold under the Pharmaton brand, Boehringer said. The option is currently being discussed with financial consultants though no decision has as yet been made, the firm maintains...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.